规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
BTK (IC50 = 37.9 nM)
|
---|---|
体外研究 (In Vitro) |
Evobrutinib 能够阻断 BTK 活性并阻止 BCR 信号通路被激活。它通过 GSH 结合、O-脱烷基化、羟基化、水解和葡萄糖醛酸化进行分解[2]。
|
体内研究 (In Vivo) |
Evobrutinib 是一种新型、高选择性、不可逆的 BTK 抑制剂,可有效阻断 Fc 和 BCR 受体介导的信号传导。
|
动物实验 |
DBA/1J female mice
12 mg/kg o.g. |
参考文献 |
分子式 |
C25H27N5O2
|
---|---|
分子量 |
429.5142
|
精确质量 |
429.22
|
元素分析 |
C, 69.91; H, 6.34; N, 16.31; O, 7.45
|
CAS号 |
1415823-73-2
|
相关CAS号 |
1415823-73-2
|
外观&性状 |
Solid powder
|
SMILES |
C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
|
InChi Key |
QUIWHXQETADMGN-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
|
化学名 |
1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
|
别名 |
MSC-2364447-C; MSC-2364447 C; M-2951; M 2951; M2951; MSC-2364447C; MSC 2364447C; MSC2364447C
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~86 mg/mL (~200.2 mM)
Ethanol: ~10 mg/mL (~23.3 mM) |
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3282 mL | 11.6412 mL | 23.2823 mL | |
5 mM | 0.4656 mL | 2.3282 mL | 4.6565 mL | |
10 mM | 0.2328 mL | 1.1641 mL | 2.3282 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04338061 | Active Recruiting |
Drug: Evobrutinib Drug: Teriflunomide |
Relapsing Multiple Sclerosis | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
July 2, 2020 | Phase 3 |
NCT04338022 | Active Recruiting |
Drug: Evobrutinib Drug: Teriflunomide |
Relapsing Multiple Sclerosis | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
June 12, 2020 | Phase 3 |
NCT02975349 | Active Recruiting |
Drug: Evobrutinib Drug: Placebo |
Relapsing-remitting Multiple Sclerosis |
EMD Serono Research & Development Institute, Inc. |
March 7, 2017 | Phase 2 |
NCT03934502 | Completed | Drug: Evobrutinib | Healthy | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
April 15, 2019 | Phase 1 |
NCT03436394 | Completed | Drug: Evobrutinib | Renal Impairment C | Merck KGaA, Darmstadt, Germany | March 21, 2018 | Phase 1 |
Figure 1. X-ray structure of BTK ligandB43bound to the BTK kinase domain.J Med Chem.2019 Aug 15. doi: 10.1021/acs.jmedchem.9b00794. th> |
---|
Figure 2. Overlay of crystal structures ofA5andA7. Figure 5. Crystal structure of evobrutinib bound to the BTK kinase domain.J Med Chem.2019 Aug 15. doi: 10.1021/acs.jmedchem.9b00794. td> |
Figure 3. PK/PD studies in mice. Figure 6. Rat CIA model: rats treated with evobrutinib, MTX, or vehicle.J Med Chem.2019 Aug 15. doi: 10.1021/acs.jmedchem.9b00794. td> |